CD40 and neoplasm: Since MBTA therapy incorporates anti-CD40 (which polarizes B cells towards an anti-tumor role), it is reasonable to suggest that B cells drive an anti-tumor immune response through their antigen presentation capacity and also the production of anti-tumor antibodies.